CIPLA's weekly performance was disappointing, with a return of -2.92%, underperforming its peers SUNPHARMA and GRASIM. The stock's volatility was moderate at 10.18%, lower than its peers DIVISLAB and GRASIM. The Sharpe Ratio of -1.15 indicates that the stock's return was not justified by its risk. Overall, CIPLA was a relatively low-risk stock this week, but its poor performance makes it an unattractive investment option.

[Volatility: 10.18%]